SCHEMBL23747196

SCHEMBL23747196

COc1ccc(F)cc1-c1ccccc1NS(C)(=O)=O

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 7/20 0.58
PGR P06401 6/20 0.58
NR3C2 P08235 6/20 0.58
AR P10275 6/20 0.58
SLC22A12 Q96S37 1/20 0.56
CDK9 P50750 2/20 0.48
ALDH1A1 P00352 3/20 0.48
ALOX5AP P20292 2/20 0.46
FEN1 P39748 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPK1 P28482 1/20 0.46
PTGS1 P23219 1/20 0.46
STAT3 P40763 1/20 0.45
CCNT1 O60563 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
PGAM1 P18669 1/20 0.44
PTK2 Q05397 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10027911 0.80 SLC22A12 (0.63) NR3C1PGRNR3C2ARSLC22A12
SCHEMBL4860020 0.77 PTGS1 (0.63) NR3C1PGRNR3C2ARSLC22A12
SCHEMBL13848266 0.76 L3MBTL1 (0.54) NR3C1PGRNR3C2ARSLC22A12
SCHEMBL8940603 0.74 ERN1 (0.51) NR3C1PGRNR3C2ARCDK9
SCHEMBL8524487 0.74 PTGS2 (0.59) NR3C1PGRNR3C2ARPTGS1
SCHEMBL20523653 0.73 SLC22A12 (0.48) NR3C1PGRNR3C2ARSLC22A12
SCHEMBL28444470 0.72 SLC22A12 (1.00) NR3C1PGRNR3C2ARSLC22A12
SCHEMBL31090892 0.71 PTGS1 (0.55) NR3C1PGRNR3C2ARALDH1A1
SCHEMBL4620558 0.71 JAK2 (0.52) NR3C1PGRNR3C2ARALDH1A1
SCHEMBL3347567 0.71 HTR7 (0.47) NR3C1NR3C2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2023-01-10 US disclosed
US-20210244717-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT Valo Health, LLC 2021-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NQO1 NR3C1 3083/4885PGR 1996/4885NR3C2 1932/4885
US-20210244717-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 NR3C1 3309/4885PGR 2952/4885NR3C2 2250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.